Literature DB >> 7965806

Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.

E Koyama1, D R Sohn, S G Shin, K Chiba, J G Shin, Y H Kim, H Echizen, T Ishizaki.   

Abstract

We studied the metabolic disposition of imipramine by measuring imipramine and its metabolites in plasma and urine simultaneously after a single oral dose of 25 mg of imipramine hydrochloride administered to 16 healthy (three Japanese and 13 Korean) volunteers. Four of the subjects were poor metabolizers (PMs) of metoprolol but extensive metabolizers (EMs) of S-mephenytoin (PMML/EMMP), five subjects were EMs of metoprolol but PMs of S-mephenytoin (EMML/PMMP) and seven subjects were EMs of both metoprolol and S-mephenytoin (EMML/EMMP). The mean (+/- S.D.) oral clearances of imipramine were smaller in the PMML/EMMP group and the EMML/PMMP group than in the EMML/EMMP group, although a statistical difference (P < .05) was found only in the EMML/PMMP vs. the EMML/EMMP group. The mean area under the plasma concentration-time curve (AUC) of desipramine was 9 times greater (P < .01) in PMML/EMMP group, whereas the mean value was 0.6 times smaller (P < .05) in the EMML/PMMP group than in the EMML/EMMP group. The log10 metoprolol/alpha-hydroxymetoprolol ratio correlated positively with the AUC of desipramine (P < .01) and with the AUC ratio of desipramine/imipramine (P < .05) but negatively with the AUC ratio of 2-hydroxyimipramine/imipramine (P < .05). Log10 percent 4'-hydroxymephenytoin excreted in 8-hr urine correlated positively with the AUC of desipramine (P < .01) and with the AUC ratio of desipramine/imipramine (P < .01). The urinary excretions of imipramine and its metabolites also reflected the data derived from plasma samples in the three different phenotype-paired panels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965806

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.

Authors:  S L Bramer; A Suri
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

2.  Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity.

Authors:  Jennifer Cohen Smith; Steven C Curry
Journal:  J Med Toxicol       Date:  2011-09

3.  The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.

Authors:  K Kobayashi; T Yamamoto; K Chiba; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 5.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Prediction of Metabolite-to-Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model.

Authors:  Ernesto Callegari; Manthena V S Varma; R Scott Obach
Journal:  Clin Transl Sci       Date:  2020-02-04       Impact factor: 4.689

8.  Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study.

Authors:  Victoria Rollason; Célia Lloret-Linares; Kuntheavy Ing Lorenzini; Youssef Daali; Marianne Gex-Fabry; Valérie Piguet; Marie Besson; Caroline Samer; Jules Desmeules
Journal:  J Pers Med       Date:  2020-10-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.